SecBot SecBot
Insider Cluster (2 insiders) ·Filed Sep 10, 2026

UTHR

UNITED THERAPEUTICS Corp
MIXED
Impact 4/10
Horizonweeks Processed2mo ago
Insider cluster: 2 insiders, $1.8M total
Actionable Insight ◆ Mixed

The CEO's concentrated selling alongside a large buyback creates a tension: the buyback signals management's view that shares are undervalued, but the CEO's personal selling suggests otherwise. Monitor for any subsequent Form 4 filings from other C-suite executives, if additional insiders sell, the bearish signal strengthens. The ASR's final settlement in Q4 2026 will determine actual share retirement; track VWAP during the term for buyback efficiency.

DirectionMixed
Confidencemedium
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$497.11
T+0 close · Sep 10, 2026 · via day close
Latest settled
+10.47%
T+20 · $549.16 · next T+60 in 20d
Vs SPY
+8.60%
α at T+20
Latest observation
+20.22%
T+44 · FF3 residual α
  1. T+0 · Sep 11 $497.11entry
  2. T+1 · 2mo ago +1.12%α +1.57% · $502.70
  3. T+5 · 2mo ago −0.50%α −0.16% · $494.63
  4. T+20 · 6w ago +10.47%α +8.60% · $549.16
  5. T+46 · todayOpen
  6. T+60 · in 20d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CEO Martine Rothblatt sold ~$5.9M of UTHR stock over two days (Sep 8-9), including shares acquired via option exercises at $117.76, while EVP & General Counsel Paul Mahon sold $1.13M on Sep 3. The sales coincide with the company's announcement of a $477.6M accelerated share repurchase (ASR) agreement with Citibank on Sep 8. The CEO's large-scale selling alongside a major capital return program creates a mixed signal, the buyback is credit-positive and reduces share count, but insider sales of this magnitude by the top executive warrant caution. At ~0.03% of market cap, the total open-market sales are trivial in proportion, but the CEO's concentrated selling pattern is notable given her insider status and the proximity to the ASR announcement.

Key Financial Metrics

Direction
selling
Total Value
$1.8M
Insiders
2

Key Facts

  • CEO Martine Rothblatt sold ~$5.9M in open-market sales over Sep 8-9, including shares from option exercises at $117.76 strike price.
  • EVP & General Counsel Paul Mahon sold $1.13M on Sep 3.
  • Company announced $477.6M accelerated share repurchase (ASR) agreement with Citibank on Sep 8, receiving ~719,376 initial shares.
  • Total open-market insider sales of ~$7.0M represent ~0.03% of UTHR's $21.7B market cap, trivial proportionally.
  • The ASR is expected to settle in Q4 2026, with final share count based on VWAP during the term.

Financial Impact

CEO sold ~$5.9M and GC sold $1.13M in open-market sales; company committed $477.6M to share buyback via ASR

share countcash deploymentinsider ownership

Risk Factors

  • CEO selling may indicate lack of confidence despite buyback announcement
  • ASR final settlement could result in fewer shares repurchased if stock price rises during the term
  • No other C-suite insiders bought shares to offset the selling pattern

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-UTHR-1789106552984

Track record

123 reports on UTHR

Performance horizon

4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 5 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today Insider Cluster Neutral 3/10 Entry price pending
  2. Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
  3. Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
  4. Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
  5. Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
  6. Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
  7. Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
  8. Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
  9. Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
  10. Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
Showing 10 of 123

US Market Status

Market Closed · Opens Wed (10h 38m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 11, 2026